Phase 3 Melanoma Trial, Recruiting NCT06007690 Sponsor: Aura Biosciences Condition: Melanoma
Back to Melanoma

Phase 3 Melanoma Trial, Recruiting

NCT06007690
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been clinically diagnosed with a primary indeterminate lesion or small choroidal melanoma (a type of eye tumour) (confirm with trial site)
  • People whose imaging results show no signs that the condition has spread to other parts of the body
  • People who have not previously received treatment for their indeterminate lesion or small choroidal melanoma, although those who have had a treatment called PDT (photodynamic therapy) may still be eligible

Who may not be able to join:

  • People who have known allergies, sensitivities, or medical reasons why they cannot receive the study drug or the laser used in the trial
  • People who currently have an active infection or disease affecting the eye

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Medical Monitor, Aura Biosciences

Phone: 617-500-8864

Australian sites

Terrace Eye Centre, Brisbane, Queensland
Eye Research Australia, East Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Aura Biosciences
Registry
ClinicalTrials.gov
Start date
6 December 2023
Est. completion
15 November 2027

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇨🇦 Canada 🇨🇿 Czechia 🇫🇷 France 🇩🇪 Germany 🇮🇱 Israel 🇮🇹 Italy 🇳🇱 Netherlands 🇳🇿 New Zealand 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Time to reach tumor progression

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov